Fil LTD Denali Therapeutics Inc. Transaction History

Fil LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$14.2 - $27.98 $5.34 Million - $10.5 Million	-376,364 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$18.5 - $28.14 $16.5 Million - $25.1 Million	-892,672 Reduced 70.34%	376,364 $7.81 Million
Q1 2019 May 13, 2019	SELL	$17.99 - $24.65 $2.3 Million - $3.15 Million	-127,849 Reduced 9.15%	1,269,036 $29.5 Million
Q4 2018 Feb 13, 2019	SELL	$13.88 - $21.75 $19.3 Million - $30.2 Million	-1,390,094 Reduced 49.88%	1,396,885 $28.9 Million
Q3 2018 Nov 09, 2018	SELL	$12.46 - $21.74 $21.8 Million - $38 Million	-1,749,736 Reduced 38.57%	2,786,979 $60.6 Million
Q2 2018 Aug 10, 2018	BUY	$15.25 - $21.02 $5.36 Million - $7.39 Million	351,733 Added 8.4%	4,536,715 $69.2 Million
Q4 2017 Feb 12, 2018	BUY	$15.04 - $21.45 $62.9 Million - $89.8 Million	4,184,982	4,184,982 $65.5 Million

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Fil LTD, based on Form 13F filings with the SEC.

Stay updated on Fil LTD with notifications on news.